Skip to main content

Advertisement

SpringerLink
Log in

In Vitro and In Vivo Assessment of Designed Melphalan Loaded Stealth Solid Lipid Nanoparticles for Parenteral Delivery

  • Published:
BioNanoScience Aims and scope Submit manuscript

Abstract

The aim of the present study is to develop the melphalan (MLN) loaded stealth solid lipid nanoparticles (SSLNs) for parenteral delivery by hot homogenization technique using central composite design. Amount of tristearin, soyalecithin, and DSPE-m-PEG-2000 is taken as independent factor whereas the particle size, % of encapsulation efficiency, and zeta potential are considered as dependent factors. Developed SSLNs were characterized through various physicochemical parameters, i.e., percentage of drug content, particle size, zeta potential, polydispersity, and percent encapsulation efficiency. The SSLNs were optimized using desirability and overlay plots, and optimized SSLNs were further characterized for various physicochemical parameters, i.e., in vitro drug release at pH 7.4, 6.5 and 5.5 by dialysis process, drug and excipient compatibility analysis (FTIR, DSC, TGA, SEM, and XRD), sterilization, in vitro cell viability and hematological studies, in vivo pharmacokinetics on rats, and stability, respectively. The % assay was found in the range 97.89 ± 0.9 to 101 ± 1.6%; particle size was found in the range of 106 ± 0.9 to 301 ± 1.2 nm whereas the zeta potential was found in the range of − 4 to -38 mV, respectively. The drug release of SSLN was found at around 100% at 28, 32, and 34 h for pH 7.4, 6.5 and 5.5 mediums, respectively. The lyophilized form of SSLNs showed better stability compared with SSLN suspension. The in vitro cell viability studies indicated that SSLNs showed superior results compared with their pure MLN solution. The in vivo pharmacokinetic studies revealed that SSLNs showed long circulation (t1/2), better residence time (MRT), and low elimination rate (Kel) compared with pure MLN solution. Melphalan loaded stealth solid lipid nanoparticles were successfully designed using central composite design by high-pressure homogenization with low particle size and high encapsulation efficiency (92%) and are able to release the drug in controlled manner.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Wu, X. Z. (2006). A new classification system of anticancer drugs based on cell biological mechanisms. Med Hypotheses, 66(5), 883–887. https://doi.org/10.1016/j.mehy.2005.11.036.

    Article  Google Scholar 

  2. Das, M., Mohanty, C., & Sahoo, S. K. (2009). Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv, 6(3), 285–304. https://doi.org/10.1517/17425240902780166.

    Article  Google Scholar 

  3. Casonova, F., Quarti, J., da Costa, D. C., Ramos, C. A., da Silva, J. L., & Fialho, E. (2012). Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. J Cell Biochem, 113(8), 2586–2596. https://doi.org/10.1002/jcb.24134.

    Article  Google Scholar 

  4. https://www.drugbank.ca/drugs/DB01042. Accessed on 05/07/2016

  5. https://www.rxlist.com/alkeran-drug.htm. Accessed on 05/07/2016

  6. Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016). Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev, 68(3), 701–787. https://doi.org/10.1124/pr.115.012070.

    Article  Google Scholar 

  7. Gregoriadis, G. (2018). Liposomology: delivering the message. J Liposome Res, 28(1), 1532–2394. https://doi.org/10.1080/08982104.2018.1429356.

    Article  Google Scholar 

  8. https://www.doxil.com.

  9. Gabizon, A. A. (2001). Stealth liposomes and tumor targeting: one step further in the quest for magic Bullet. Clin. Cancer Res, 7(2), 223–225 https://www.ncbi.nlm.nih.gov/pubmed/11234871.

    Google Scholar 

  10. Lucks, S., & M & s:, R. R.. (1999a). Medication vehicles made of solid lipid particles (solid lipid nanospheres-SLN),EP0605497B2.(1999a). https://patents.google.com/patent/EP0605497B2/hr

  11. Muhlen Zur, A., Schwarz, C., & Mehnert, W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45(2), 149–155. https://doi.org/10.1016/S0939-6411(97)00150-1.

    Article  Google Scholar 

  12. Cerpnjak, K., Zvonar, A., Gasperlin, M., & Vrecer, F. (2013). Lipid-based systems as promising approach, for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharma, 63(4), 427–445. https://doi.org/10.2478/acph-2013-0040.

    Article  Google Scholar 

  13. Fahr, A., & Liu, X. (2007). Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv, 4(4), 403–416. https://doi.org/10.1517/17425247.4.4.403.

    Article  Google Scholar 

  14. Bunies, H. (2010). Lipid nanoparticles for the delivery of poorly water-soluble drugs. J Pharm Pharmacol, 62(11), 1637–1645. https://doi.org/10.1111/j.2042-7158.2010.01024.x.

    Article  Google Scholar 

  15. Fufundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res, 42(4), 337–343. https://doi.org/10.1006/phrs.2000.0695.

    Article  Google Scholar 

  16. Kuznetsova, N. R., Stepanova, E. V., Peretolchina, N. M., Khochenkov, D. A., Boldyrev, I. A., Bovin, N. V., & Vodovozova, E. L. (2014). Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the sialyl Lewis X selectin ligand. J Drug Target, 22(3), 242–250. https://doi.org/10.3109/1061186X.2013.862805.

    Article  Google Scholar 

  17. Chelvi, T. P., & Ralhan, R. (1997). Hyperthermia potentiates antitumor effect of thermosensitive-liposome-encapsulated melphalan and radiation in murine melanoma. Tumor Biol, 18(4), 250–260 https://www.ncbi.nlm.nih.gov/pubmed/9218010.

    Article  Google Scholar 

  18. Stella, B., Peira, E., Dianzani, C., Gallarate, M., Battaglia, L., Gigliotti, C. L., Boggio, E., Dianzani, U., & Dosio, F. (2018). Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative. Nanomaterials, 8(2), 110. https://doi.org/10.3390/nano8020110.

    Article  Google Scholar 

  19. Raju, K. K., Sudhakar, B., & Ramana Murthy, K. V. (2014). Factorial design studies and biopharmaceutical evaluation of simvastatin loaded solid lipid nanoparticles for improving the oral bioavailability. ISRN Nanotechnology Article ID, 951016, 1–8. https://doi.org/10.1155/2014/951016.

    Article  Google Scholar 

  20. Bodratti, A., & Alexandridis, P. (2018). Formulation of poloxamers for drug delivery. J Funct Biomater, 9(1), 11. https://doi.org/10.3390/jfb9010011.

    Article  Google Scholar 

  21. Singh, R., & Lillard Jr., J. W. (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004.

    Article  Google Scholar 

  22. Mehnert, W., & Mander, K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 64, 83–101. https://doi.org/10.1016/j.addr.2012.09.021.

    Article  Google Scholar 

  23. Zhao, Y., Wang, L., Yan, M., et al. (2012). Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nano medicine, 7, 2891–2900. https://doi.org/10.2147/IJN.S30943.

    Article  Google Scholar 

  24. Brightman, K., Finlay, G., Jarvis, I., Knowlton, T., & Manktelow, C. T. (1999). A stability-indicating method for the determination of melphalan and related impurity content by gradient HPLC. J Pharm Pharm Sci, 20(3), 439–447. https://doi.org/10.1016/S0731-7085(99)00011-4.

    Article  Google Scholar 

  25. Pinguet, F., Joulia, J. M., Martel, P., Grosse, P. Y., Astre, C., & Bressolle, F. (1996). High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokineticstudies, J Chromatogr B, 686(1), 43–49. https://doi.org/10.1016/S0378-4347(96)00184-3.

    Article  Google Scholar 

  26. Varshosaz, J., Ghaffari, S., Khoshayand, M. R., Atyabi, F., Azarmi, S., & Kobarfard, F. (2010). Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J Liposome Res, 20(2), 97–104. https://doi.org/10.3109/08982100903103904.

    Article  Google Scholar 

  27. Sudhakar, B., Krishna, M. C., & Murthy, K. V. R. (2016). Factorial design studies of antiretroviral drug-loaded stealth liposomal injectable PEGylation, lyophilization and pharmacokinetic studies. Appl Nanosci, 6(1), 43–60. https://doi.org/10.1007/s13204-015-0408-8.

    Article  Google Scholar 

  28. Arjun, N., & Veerabrahma, K. (2013). Preparation characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability. J Pharm Sci Article ID, 265741, 1–7. https://doi.org/10.1155/2013/265741.

    Article  Google Scholar 

  29. Wesley, N. O., Bernhards, O., Florence, O., Hulda Swai, L. K., Paula, M., Geoffrey, M. M., & Jeremiah, W. G. (2014). Preparation characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int J Nanomed, 9(1), 3865–3874. https://doi.org/10.2147/IJN.S62630.

    Article  Google Scholar 

  30. Rosa, G. D., Stefano, M. D., Ungaro, F., & Rotonda, M. L. (2008). Cold field emission gun-scanning electron microscopy: new tool for morphological and ultrastructural analysis of liposomes. Int J Pharm, 362(1-2), 189–192. https://doi.org/10.1016/j.ijpharm.2008.06.003.

    Article  Google Scholar 

  31. Costa, P., & Jose, M. S. L. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13(2), 123–133. https://doi.org/10.1016/S0928-0987(01)00095-1.

    Article  Google Scholar 

  32. Peppas, N. A. (1985). Analysis of fickian and non-fickian drug release from polymers. Pharm Acta Helv, 60(4), 110–111 https://www.ncbi.nlm.nih.gov/pubmed/4011621.

    Google Scholar 

  33. Howard, M. D., Lu, X., Jay, M., & Dziubla, T. D. (2012). Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles. Drug Dev Ind Pharm, 38(10), 1270–1279. https://doi.org/10.3109/03639045.2011.645835.

    Article  Google Scholar 

  34. Cherry, C. L. A., Millward, H., Cooper, R., & Landon, J. (2014). A novel approach to sterile pharmaceutical freeze-drying. Pharm Dev Technol, 19(1), 73–81. https://doi.org/10.3109/10837450.2012.752388.

    Article  Google Scholar 

  35. Sanyog, J. S., Jagadish, M. S., Amit, K. J., & Rahul, R. M. (2013). Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nano medicine, 8(10), 1639–1655. https://doi.org/10.2217/nnm.12.181.

    Article  Google Scholar 

  36. http://www.ich.org/products/guidelines/quality/quality-single/article/stability-testing-of-new-drug-substances-and-products.html. Accessed on 06/07/02017.

  37. Mahesh, G. A., Narsireddy, A., Madhusudana Rao, N., & Manorama, V. S. (2018). A simple approach to design chitosan functionalized Fe3O4 nanoparticles for pH responsive delivery of doxorubicin for cancer therapy. J Magn Mag Mater, 448, 199–207. https://doi.org/10.1016/j.jmmm.2017.09.018.

    Article  Google Scholar 

  38. Suelen, P. F., Debora, B. S., Pedro, V. A. B., Paulo, R. S., Luana, C. F., Heveline, D. M. F., Catia, S. N., Johny, P. M., Elton, G. B., Celso, V. N., Edvani, C. M., & Alessandro, F. M. (2016). Preparation and cytotoxicity of N-modified chitosan nanoparticles applied in curcumin delivery. Int J Biol Macromol, 87, 237–245. https://doi.org/10.1016/j.ijbiomac.2016.02.063.

    Article  Google Scholar 

  39. Barbara, S., Elena, P., Chiara, D., Marina, G., Luigi, B., Casimiro, L. G., Elena, B., Umberto, D., & Franco, D. (2018). Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative. Nanomaterials, 8, 110. https://doi.org/10.3390/nano8020110.

    Article  Google Scholar 

  40. Petterino, C., & Argentino, S. A. (2006). Clinical chemistry and haematolofy historical data in Sprague-Dawley rats from pre-clinical toxicity studies. Exp Toxicol Pathol, 57(3), 213–219. https://doi.org/10.1016/j.etp.2005.10.002.

    Article  Google Scholar 

  41. Said, N. M., & Abiola, O. (2014). Haematological profile shows that inbred Sprague Dawley rats have exceptional promise for use in biomedical and pharmacological studies. Asian J Pharm, 4(37), 33–37. https://doi.org/10.15272/ajbps.v4i37.597.

    Article  Google Scholar 

  42. Limit size lipid nanoparticles and related methods. US 2014/0328759 A1. https://patents.google.com/patent/US20140328759A1/en.

  43. Garbuzenko, O., Zalipsky, S., Qazen, M., & Barenholz, Y. (2005). Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir, 21(6), 2560–2568. https://doi.org/10.1021/la0479105.

    Article  Google Scholar 

  44. Shlear, H. H., & Nabeel, S. Othman, Kafia M. Surchi. (2013) Solid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterization. European Scientific journal ESJ 3: 779-798. https://doi.org/10.19044/esj.2013.v9n21p%25p.

  45. Syed, A. A. R., & Saleh, A. M. (2018). Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J, 26(1), 64–70. https://doi.org/10.1016/j.jsps.2017.10.012.

    Article  Google Scholar 

  46. Zur, M. A., Schwarz, C., & Mehnert, W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery—drug release and release mechanism. Eur J Pharm Biopharm, 45(2), 149–155. https://doi.org/10.1016/S0939-6411(97)00150-1.

    Article  Google Scholar 

  47. https://www.pda.org/.../defining-a-strategy-for-the-validation-and-qualification. Accessed on 23/07/2019.

  48. Patravale, V. B., & Ambarkhane, A. V. (2003). Study of solid lipid nanoparticles with respect to particle size distribution and drug loading. Pharmazie, 58(6), 392–395 https://www.ncbi.nlm.nih.gov/pubmed/12857001.

    Google Scholar 

  49. George, G. B., & Parker, K. (2003). Understanding the complete blood count with differential. J PeriAnesth Nurs, 18(2), 96–117. https://doi.org/10.1053/jpan.2003.50013.

    Article  Google Scholar 

  50. Chow, P. K., Robert, T. H. N., & Bryan, E. O. (2008). Using animal models in biomedical research, the rationale for the use of animal models in Bio medical research. World scientific, 308. https://doi.org/10.1142/6454.

  51. Peng., Z., Lawrence, H., Anirban, M., Stephan, T. S., & Scott, E. M. (2013). Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm, 10(5), 1977–1987. https://doi.org/10.1021/mp4000019.

    Article  Google Scholar 

  52. Ihedioha, J. I., Okafor, C., & Ihedioha, T. E. (2004). The haematological profile of the Sprague-Dawley outbred albino rat in Nsukka, Nigeria. Animal Research International, 1(2), 125–132. https://doi.org/10.4314/ari.v1i2.40755.

    Article  Google Scholar 

Download references

Availability of data and materials

Available upon the request

Author information

Authors and Affiliations

  1. Department of Chemistry, GITAM Institute of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India

    V. S. A. Pavan Rudhrabatla & K. V. N. Suresh Reddy

  2. Department of Pharmaceutical Technology, A.U. College of Pharmaceutical Sciences, Andhra University, Vishakhapatnam, Andhra Pradesh, 530003, India

    Beeravelli Sudhakar

Authors
  1. V. S. A. Pavan Rudhrabatla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beeravelli Sudhakar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. V. N. Suresh Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KVNSR is the main author of the study; BS is involved in designing the graphs, and VSAPR performed the experiments, interpreted the data, and wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to K. V. N. Suresh Reddy.

Ethics declarations

The protocol for the in vivo experiments has been approved by the Institute of Animal Ethics Committee (IAEC) of CPCSEA, India (Protocol No. Ref. No/IAEC/XII/01/SIPS/2017-2018).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rudhrabatla, V.S.A.P., Sudhakar, B. & Reddy, K.V.N.S. In Vitro and In Vivo Assessment of Designed Melphalan Loaded Stealth Solid Lipid Nanoparticles for Parenteral Delivery. BioNanoSci. 10, 168–190 (2020). https://doi.org/10.1007/s12668-019-00680-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12668-019-00680-6

Keywords

Search

Navigation